Bozeman, MT 9/30/3025 – Montana Molecular is celebrating the start of a new award from the National Cancer Institute at the National Institutes of Health. The company, based in Bozeman, Montana, is using a machine learning approach to design the structure of a new class of fluorescent biosensor molecules that will illuminate G-Protein Coupled Receptor (GPCR) signaling through the G12/13 pathway.
Many GPCRs that signal through G12/13 are promising targets for new cancer treatments because when G12/13 signaling goes off the track, the result is cancer – including tumor cell growth, cell migration and immune system evasion. Montana Molecular’s project to build new biosensors will provide the assays needed to measure this pathway enabling researchers to develop more effective cancer treatments.
“Biosensors that measure GPCR signaling in living cells empower scientists to understand disease pathways and evaluate the biological effects of drugs before advancing to trials in patients,” said Anne Marie Quinn, Founder and CEO of Montana Molecular. “This project underscores our commitment to innovation in drug discovery with a focus on cancer research.”
Principal Investigators, Thomas E. Hughes, and Luciana M. Leo, will be joined on this project by Stephen R. Sprang, a pioneer in the structure determination of G-proteins, their effectors and chaperones, as well as Sam Hoare, GPCR pharmacologist and renowned expert in live cell signaling analysis. Find more information about award (R43CA29529) or by reaching out directly to Montana Molecular at info@montanamolecular.com.
About Montana Molecular:
Montana Molecular, based in Bozeman, MT, specializes in developing innovative fluorescent biosensors that reveal how signaling pathways respond to candidate therapeutics. By providing researchers with cutting-edge tools, the company accelerates discovery in diabetes and obesity, neuroscience, and beyond.
